RESULTS OF PHASE II STUDY OF COMBINED IMMUNOTHERAPY WITH RITUXIMAB PLUS LYMPHOKINE‐ACTIVATED KILLER CELLS AS MAINTENANCE IN FOLLICULAR LYMPHOMA PATIENTS. (12th June 2019) - Martinez Calle, N.; Diaz De Cerio, A.; Pena, E.; Garcia Muñoz, R.; Panizo, A.; Feliu, J.; Giraldo, P.; Rodriguez, M.; Grande, C.; Olave, T.; Andrade‐Campos, M.; Bandres, E.; et al.